Establishing an Anti-Müllerian Hormone Cutoff for Diagnosis of Polycystic Ovarian Syndrome in Women of Reproductive Age-Bearing Indian Ethnicity Using the Automated Anti-Müllerian Hormone Assay
- PMID: 31293324
- PMCID: PMC6594116
- DOI: 10.4103/jhrs.JHRS_149_18
Establishing an Anti-Müllerian Hormone Cutoff for Diagnosis of Polycystic Ovarian Syndrome in Women of Reproductive Age-Bearing Indian Ethnicity Using the Automated Anti-Müllerian Hormone Assay
Abstract
Context: Polycystic ovary syndrome diagnosed by Rotterdam criteria, is the most common cause of anovulatory infertility. The criteria of polycystic ovarian morphology (PCOM) are subject to operator variability and technological advances. Serum anti-Müllerian hormone (AMH) level has been proposed as a more reliable alternative to antral follicle count. There is a paucity of data on use of AMH for diagnosis of PCOS in Indian women.
Aim and objectives: The aim of this study is to determine a cutoff level for AMH that could facilitate diagnosis of PCOS and its phenotypes in women of Indian origin using the automated (Roche) assay and to compare the competence of oocytes in PCOS and non-PCOS women undergoing in vitro fertilization-intracytoplasmic sperm injection (IVF-ICSI).
Materials and methodology: A total of 367 women undergoing treatment at our fertility center between February 2017 and August 2017 were prospectively enrolled in this study. Of these, 133 were diagnosed with PCOS, 69 had isolated PCOM, and 165 (controls) had normal ovaries on ultrasound examination. Serum AMH levels were assessed using the fully automated Roche Elecsys® immunoassay. Gonadotropin-releasing hormone antagonist protocol was used for IVF-ICSI in all patients.
Statistical analysis used: Quantitative variables were compared using the Mann-Whitney test. Qualitative variables were correlated using the Chi-square test. P < 0.05 was considered to be statistically significant.
Results: Mean AMH concentrations in women with PCOS was higher (7.56 ± 4.36 ng/mL) in comparison to PCOM and controls. Serum AMH concentration >5.03 ng/mL could facilitate diagnosis of PCOS (area under the curve = 0.826); sensitivity -70.68%, specificity of 79.91%. There was no difference in the ratio of mature to total oocytes retrieved in the three groups (P > 0.05). Mean number of mature oocytes was lower in controls than PCOS and PCOM (P < 0.001).
Conclusions: Serum AMH concentration >5.03 ng/mL could be used as cutoff value for the diagnosis of PCOS in women of Indian origin.
Keywords: Anti-Müllerian hormone; Rotterdam criteria; ovarian reserve; polycystic ovarian syndrome.
Conflict of interest statement
There are no conflicts of interest.
Figures






Similar articles
-
Validation of an Anti-Müllerian Hormone Cutoff for Polycystic Ovarian Morphology in the Diagnosis of Polycystic Ovary Syndrome in the HARMONIA Study: Protocol for a Prospective, Noninterventional Study.JMIR Res Protoc. 2024 Feb 6;13:e48854. doi: 10.2196/48854. JMIR Res Protoc. 2024. PMID: 38319689 Free PMC article.
-
Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis.Hum Reprod. 2017 Aug 1;32(8):1723-1731. doi: 10.1093/humrep/dex226. Hum Reprod. 2017. PMID: 28854584
-
Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study.Hum Reprod. 2021 Dec 27;37(1):109-118. doi: 10.1093/humrep/deab232. Hum Reprod. 2021. PMID: 34741176
-
Anti-Müllerian hormone levels in the diagnosis of adolescent polycystic ovarian syndrome: a systematic review and meta-analysis.Endocr J. 2022 Aug 29;69(8):897-906. doi: 10.1507/endocrj.EJ22-0081. Epub 2022 Jun 8. Endocr J. 2022. PMID: 35675999
-
Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society.Hum Reprod Update. 2014 May-Jun;20(3):334-52. doi: 10.1093/humupd/dmt061. Epub 2013 Dec 16. Hum Reprod Update. 2014. PMID: 24345633
Cited by
-
Anti-Müllerian Hormone Predictive Levels to Determine The Likelihood of Ovarian Hyper-Response in Infertile Women with Polycystic Ovarian Morphology.Int J Fertil Steril. 2021 Apr;15(2):115-122. doi: 10.22074/IJFS.2020.134614. Epub 2021 Mar 11. Int J Fertil Steril. 2021. PMID: 33687164 Free PMC article.
-
Ovarian Stimulation in Assisted Reproductive Technology Cycles for Varied Patient Profiles: An Indian Perspective.J Hum Reprod Sci. 2022 Apr-Jun;15(2):112-125. doi: 10.4103/jhrs.jhrs_59_22. Epub 2022 Jun 30. J Hum Reprod Sci. 2022. PMID: 35928474 Free PMC article. Review.
-
The Role of Serum Anti-Mullerian Hormone Measurement in the Diagnosis of Polycystic Ovary Syndrome.Diagnostics (Basel). 2023 Feb 27;13(5):907. doi: 10.3390/diagnostics13050907. Diagnostics (Basel). 2023. PMID: 36900051 Free PMC article. Review.
-
Diagnostic Utility of Various Hormones across Different Polycystic Ovary Syndrome Phenotypes: A Cross-sectional Study.J Hum Reprod Sci. 2024 Oct-Dec;17(4):275-283. doi: 10.4103/jhrs.jhrs_152_24. Epub 2024 Dec 23. J Hum Reprod Sci. 2024. PMID: 39831099 Free PMC article.
References
-
- Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update. 1997;3:359–65. - PubMed
-
- Puurunen J, Piltonen T, Morin-Papunen L, Perheentupa A, Järvelä I, Ruokonen A, et al. Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metab. 2011;96:1827–34. - PubMed
-
- Wissing ML, Bjerge MR, Olesen AI, Hoest T, Mikkelsen AL. Impact of PCOS on early embryo cleavage kinetics. Reprod Biomed Online. 2014;28:508–14. - PubMed
-
- Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6–15. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources